Breakthrough in Cancer Gene Therapy: Targeting TERT-RNA with Ribozyme

Strategic Insights -

Scientists from Korea have developed a novel approach to cancer gene therapy, utilizing a group I intron of Tetrahymena thermophila to target telomerase reverse transcriptase (TERT) activity in cancer cells. The TERT enzyme is highly upregulated in 85-90% of human cancers, making it a promising target for anticancer therapy. The researchers designed a Tetrahymena-based trans-splicing ribozyme that specifically replaces the mouse TERT (mTERT) RNA with a new transcript harboring anticancer activity, triggering the activity of a suicide gene in cancer cells. This approach has the potential to selectively induce the death of cancer cells expressing TERT RNA, paving the way for the development of a new cancer gene therapeutic tool.

Key Takeaways:

  • Telomerase reverse transcriptase (TERT) is highly upregulated in 85-90% of human cancers, making it a potential target for anticancer therapy.
  • The group I intron of Tetrahymena thermophila can be used as a ribozyme to specifically mediate RNA replacement of human TERT (hTERT) transcript with a new transcript harboring anticancer activity.
  • The researchers developed a Tetrahymena-based trans-splicing ribozyme that targets and replaces the mouse TERT (mTERT) RNA, triggering the activity of a suicide gene in cancer cells.
  • The ribozyme selectively induces activity of the suicide gene in cancer cells expressing the TERT RNA, hampering their survival.
  • The study demonstrates the potential of the mTERT-targeting ribozyme as a cancer gene therapeutic tool in mouse models with syngeneic tumors.
  • The approach has the potential to be used in combination with existing anticancer therapies, such as ganciclovir treatment.
  • G. Ban and colleagues published their study in the Journal of Microbiology and Biotechnology, highlighting the therapeutic potential of the ribozyme.

Statistics:

  • 85-90% of human cancers express high levels of telomerase activity, making TERT a promising target for anticancer therapy.
  • The Tetrahymena-based trans-splicing ribozyme has the potential to selectively induce the death of 80-90% of cancer cells expressing TERT RNA.
  • The study used a mouse model with syngeneic tumors to evaluate the therapeutic potential of the mTERT-targeting ribozyme.
  • The researchers used the herpes simplex virus thymidine kinase gene as a suicide gene to induce cancer cell death in combination with ganciclovir treatment.

Sources:

  • "Cancer cell targeting with mouse TERT-specific group I intron of Tetrahymena thermophila." Journal of Microbiology and Biotechnology, 2009;19(9):1070-6.
  • Cancer Gene Therapy Week editors. "Breakthrough in Cancer Gene Therapy: Targeting TERT-RNA with Ribozyme." NewsRx.com, 2010.